Moffitt Cancer Center
Magnolia Campus
Tampa, FL
Accepting patients
ELEMENT-MDS
Phase 3 Clinical Trial Comparing Luspatercept VS Epoetin Alfa in Patients with Very Low – Intermediate Risk MDS Who Are Not Transfusion Dependent
- Erythroid Maturation Agent (EMA)
- Erythropoiesis-Stimulating Agent (ESA)
- Red Blood Cell Stimulant
- Phase 3
Accepting patients
DFV890
A Phase 1b, Open Label, Multi-center, Dose Optimization and Dose Expansion Study to Assess the Safety and Efficacy of DFV890 in Adult Patients With Myeloid Diseases
- NLRP3 Inhibitor
- Phase 1
- Has results
Accepting patients
REM-422
A Phase 1, Multicenter, Open-Label Study of REM-422, an MYB mRNA Degrader, in Patients With Relapsed/Refractory AML or Higher-Risk MDS
- MYB mRNA Degrader
- Phase 1
Accepting patients
ACCESS
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide (ACCESS)
- Allogeneic Stem Cell Transplant
- Pre-Transplant
- Phase 2
Accepting patients
OPTIMIZE
A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients With Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Allogeneic Stem Cell Transplant
- Phase 2
Accepting patients
BH-30236
A Phase 1/1b Open-Label, Dose Escalation, First-in- Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-leukemic Activity of the Orally Available CDC-Like Kinase (CLK) Inhibitor, BH-30236, in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML) or Higher-Risk Myelodysplastic Syndrome (HR-MDS)
- CLK Inhibitor
- Phase 1
Accepting patients
RAPID
A Phase 1 Study of Allogenic Off-the-Shelf Multi-Tumor-Associated Antigen-Specific T Cell Products (MT-401-OTS) Administered to Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndromes (RAPID)
- T Cell (Allogeneic)
- High Risk
- Phase 1
Accepting patients
A Phase 2, Single Arm Study of Luspatercept for the Treatment of Anemia in Lower Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Myelodysplastic Syndromes/ Myeloproliferative Neoplasms (MDS/MPN)
- Erythroid Maturation Agent (EMA)
- Red Blood Cell Stimulant
- Phase 2
Accepting patients
KER-050
A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
- Growth Factor
- Phase 2
- Has results
Accepting patients
TakeAim
TakeAim Leukemia: A Phase 1/2A, Open Label Dose Escalation and Expansion Study of Orally Administered CA-4948 as a Monotherapy in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome and in Combination With Azacitidine or Venetoclax
- BCL-2 Inhibitor
- Hypomethylating Agents (HMA)
- IRAK 4 Inhibitor
- Phase 1/2
- Has results